DTC
CYTK icon

Deep Track Capital’s Cytokinetics CYTK Stock Holding History

Deep Track Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,347,300
Closed -$112M – 69
2023
Q4 		$112M Buy
+1,347,300
New +$48.8M 3.76% 6

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deep Track Capital's CYTK Position: Q1 2026 in Review

Deep Track Capital reduced its Cytokinetics (CYTK) stake by 59% in Q1 2026, selling an estimated $125M and leaving 1,374,320 shares worth $90.6M. The position accounts for 1.48% of the portfolio, ranked #21.

Deep Track Capital first reported a position in CYTK in Q4 2023 and has held it in 9 quarters since. The position peaked at $236M in Q3 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Deep Track Capital held 1,374,320 shares of Cytokinetics worth $90.6M as of Q1 2026.
  • Deep Track Capital sold 1,962,678 Cytokinetics shares in Q1 2026, an estimated $125M.
  • Cytokinetics made up 1.48% of Deep Track Capital's portfolio in Q1 2026, its #21 holding.
  • Deep Track Capital first reported a position in Cytokinetics in Q4 2023 and has held it in 9 quarters since.
  • Deep Track Capital's Cytokinetics position peaked at $236M in Q3 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.